{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:43:01Z","timestamp":1791319381421,"version":"4.3.1"},"reference-count":11,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.jacl.2021.01.010","type":"journal-article","created":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T12:10:46Z","timestamp":1612527046000},"page":"332-338","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Characteristics and trends of PCSK9 inhibitor prescription fills in the United States"],"prefix":"10.1016","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2684-1807","authenticated-orcid":false,"given":"Sharon","family":"Attipoe-Dorcoo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Sperling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fleetwood","family":"Loustalot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela M.","family":"Thompson-Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth B.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1862-6370","authenticated-orcid":false,"given":"Soyoun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Ritchey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2021.01.010_bib1","unstructured":"AHA_ASA. Cardiovascular Disease: A Costly Burden for America \u2014 Projections through 2035. vol. 2020: American Heart Association."},{"key":"10.1016\/j.jacl.2021.01.010_bib2","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1001\/jama.2019.0015","article-title":"Management of Blood cholesterol","volume":"321","author":"Alenghat","year":"2019","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.jacl.2021.01.010_bib3","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of Blood cholesterol: a report of the American College of Cardiology\/American Heart association task force on clinical practice guidelines","volume":"73","author":"Grundy","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2021.01.010_bib5","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2021.01.010_bib6","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/S2213-8587(19)30158-5","article-title":"Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial","volume":"7","author":"Ray","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacl.2021.01.010_bib9","unstructured":"Antipolis S. Women receive less recommended drugs after a heart attack. https:\/\/www.escardio.org\/The-ESC\/Press-Office\/Press-releases\/Women-receive-less-recommended-drugs-after-a-heart-attack-bis2020."},{"key":"10.1016\/j.jacl.2021.01.010_bib10","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1161\/CIRCULATIONAHA.117.033237","article-title":"Women not receiving optimal preventive medications","volume":"137","author":"Kuehn","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2021.01.010_bib11","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1161\/CIR.0000000000000558","article-title":"Heart disease and stroke statistics\u20142018 update: a report from the American Heart association","volume":"137","author":"Benjamin","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2021.01.010_bib14","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ahj.2018.08.006","article-title":"The relationship between pharmacy benefit managers (PBMs) and the cost of therapies in the US pharmaceutical market: a policy primer for clinicians","volume":"206","author":"Schulman","year":"2018","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacl.2021.01.010_bib15","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1161\/CIRCULATIONAHA.117.028430","article-title":"Proprotein convertase subtilisin\/kexin type 9 inhibitor therapy: payer approvals and rejections, and patient characteristics for successful prescribing","volume":"136","author":"Hess","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2021.01.010_bib16","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1001\/jamacardio.2017.3451","article-title":"Association of prior authorization and out-of-pocket costs with patient access to PCSK9 inhibitor therapy","volume":"2","author":"Navar","year":"2017","journal-title":"JAMA Cardiol"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287421000271?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287421000271?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:36:13Z","timestamp":1761831373000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287421000271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":11,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S1933287421000271"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2021.01.010","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characteristics and trends of PCSK9 inhibitor prescription fills in the United States","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2021.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 National Lipid Association. All rights reserved.","name":"copyright","label":"Copyright"}]}}